Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Results There were 838 BioFINDER-2 participants (mean age, 73.9 [SD, 7.3] years; 431 women [51%]; 407 men [49%]) and 380 ADNI participants (average age, 72.9 [SD, 7.0] years; 194 women [51%]; 186 mean [49%]) included. In BioFINDER-2, 37.7% of the sample had congruent biological and clinical stages (reference group), 51.3% had more advanced clinical impairment compared with their clinical stage (clinical > biological) and 11.0% had the opposite (biological > clinical). These results highlight the importance of measuring non-AD biomarkers in patients with AD with worse cognitive impairment than expected based on their biological stage, which could impact the clinical diagnosis and prognosis.

What this study adds

Evidence grade: Moderate

This is a cross-sectional study of 838 participants. The results highlight the importance of measuring non-AD biomarkers in patients with worse cognitive impairment than expected from their biological stage, which could affect clinical diagnosis and prognosis, but no treatment, cure, or prevention is reported. Reported effect size: 37.7%; 51.3%; 11.0%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Pichet Binette, A., Smith, R., Salvadó, G., Tideman, P., Glans, I., van Westen, D., et al. (2025). Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease. JAMA neurology. https://doi.org/10.1001/jamaneurol.2025.1100

Vancouver

Pichet Binette A, Smith R, Salvadó G, Tideman P, Glans I, van Westen D, et al. Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease. JAMA neurology. 2025. doi:10.1001/jamaneurol.2025.1100. PMID: 40388185.

BibTeX

@article{pichetbinette2025-40388185,
  author  = {Pichet Binette, A. and Smith, R. and Salvadó, G. and Tideman, P. and Glans, I. and van Westen, D. and Groot, C. and Ossenkoppele, R. and others},
  title   = {{Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease}},
  journal = {JAMA neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.1100},
  pmid    = {40388185},
  url     = {https://doi.org/10.1001/jamaneurol.2025.1100}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this evaluation of revised criteria for biological and clinical staging of Alzheimer disease, only 37.7% of the BioFINDER-2 sample had congruent biological and clinical stages, while 51.3% had more advanced clinical impairment than their clinical stage and 11.0% had the opposite. The results highlight the importance of measuring non-AD biomarkers in patients with worse cognitive impairment than expected from their biological stage, which could affect clinical diagnosis and prognosis, but no treatment, cure, or prevention is reported.

Study details

How this study scored 68/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 4 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 68 of 100.68 of 100 points earned32 not earned

Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record 2 / 4 JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 838 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 63 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 21.0 citations a year over 3 year(s) since 2025
Impact for its field and year 5 / 6 Cited 39.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 8 other studies in this library
Still being cited 3 / 4 Cited 63 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Ian B. Malone: h-index 43 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 19 institution(s) in 8 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40388185)
Free to read 2 / 2 Free to read
Total 68 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Later studies that cite this one

8 studies in the alzhub library list this one in their references.

Related studies in Biomarkers from nearby years

Also in Biomarkers

141 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.

Similar studies

More on Biomarkers

See all studies in Biomarkers →